Hossein Borghaei, DO, MS, Chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, has been named one of three winners of the second annual Lung Cancer Heroes awards program. Dr. Borghaei, who is a co-leader of the Molecular Therapeutics Program at Fox Chase and an authority in the field of lung cancer immunotherapy, was recognized for his national and international service to the lung cancer community.
Hossein Borghaei, DO, MS
“I am greatly honored to receive this award, which recognizes all the patient care and cutting-edge research that takes place at Fox Chase Cancer Center,” stated Dr. Borghaei.
Dr. Borghaei, who is also the Gloria and Edmund M. Dunn Chair in Thoracic Surgical Oncology at Fox Chase, has led numerous investigator-initiated trials and was among the first to publish on the role of immunotherapy in non–small cell lung cancer in TheNew England Journal of Medicine.
The award is bestowed by CURE Media Group—a multimedia platform devoted to cancer updates, research, and education that reaches more than 1 million patients, survivors, and caregivers—in partnership with Takeda Oncology.
Mike Hennessy, Jr
“We are so excited to recognize the three winners of this year’s Lung Cancer Heroes program. With help from our friends at Takeda, I am honored to present this year’s winners. Each of these individuals exemplifies everything that a hero is to us, someone who has had a profoundly positive impact on the lives of patients with lung cancer,” said Mike Hennessy, Jr, President and Chief Executive Officer of MJH Life Science, parent company of CURE Media Group.